Allergen immunotherapy: clinical strategies for Allergy Week

Allergy Week isn’t just a calendar event, it’s a timely moment to revisit the role of allergen immunotherapy in addressing the global rise in allergic diseases. For physicians, it’s also a moment to reflect: are we offering our patients long-term solutions, or only symptom relief?

Allergen immunotherapy (AIT) has evolved from a niche intervention to a clinically validated disease-modifying strategy. When implemented correctly, it can reshape the natural course of allergic rhinitis and asthma. But it requires more than guidelines, it calls for precise clinical judgment, patient commitment, and tailored approaches.

From symptom relief to immune reprogramming

Allergen immunotherapy doesn’t just mask symptoms. It retrains the immune system to tolerate allergens that once triggered disproportionate reactions.

For your patients, this can mean:

• Fewer exacerbations during pollen season
• Reduced use of corticosteroids and antihistamines
• Long-term control of allergic rhinitis, asthma or atopic dermatitis

According to EAACI guidelines, allergen immunotherapy remains the only intervention with disease-modifying effects. Yet to achieve that, clinicians must choose the right moment, the right patient, and the right approach.

Selecting the right patients for allergen immunotherapy

Not every allergic patient is a candidate for AIT. Choosing well is key to achieving long-term control.

In An introduction to allergen immunotherapy (AIT) basics, Dr. Julien Cottet explains how to evaluate sensitization relevance, symptom correlation and comorbidities. He outlines when to initiate AIT, how to interpret skin prick and IgE results, and how to choose between sublingual and subcutaneous administration.

These are not abstract criteria, they’re framed with practical examples that reflect daily clinical dilemmas.

Adherence is not optional, it’s predictive

Even the most accurate protocol fails without patient adherence. AIT requires months, sometimes years, of consistent follow-up. Many patients drop out early, often after initial improvement, believing the therapy is complete.

InUnderstanding adherence as the cornerstone of allergen immunotherapy efficiency, Dr. Andrey Kamaev addresses this head-on. He shares actionable strategies to:

• Establish a long-term commitment during the first consultation
• Monitor adherence without overburdening the clinic
• Identify which patients are most likely to abandon treatment prematurely

These insights help prevent one of the most common pitfalls: mistaking non-adherence for therapy failure.

When standard protocols aren’t enough

Allergic patients are rarely textbook cases. Many are poly-sensitized, present overlapping exposure calendars, or live with asthma, eczema or autoimmune disease.

In Advanced understanding of allergen immunotherapy (AIT), Dr. Julien Cottet returns to address personalization. He guides physicians through:

• Adapting AIT in pregnancy or in patients on immunosuppressants
• Adjusting protocols when multiple allergens are involved
• Making clinical decisions when real-life constraints clash with textbook algorithms

These modules offer practical knowledge rooted in decades of field experience—knowledge no guideline or AI tool can replicate.

Allergy week is a call to rethink allergy care

Allergen immunotherapy is no longer an alternative, it’s a central pillar in the management of respiratory and atopic allergic disease. Mastering it can transform your clinical impact.

If you treat rhinitis, asthma or dermatitis, this is the ideal moment to refine your criteria, optimize your patient selection, and approach AIT with greater confidence.

The Xpeer allergen immunotherapy series was designed to support you in that process:

• Short, modular, accredited learning
• Built by experienced allergists
• Free and accessible anytime

Start learning today on Xpeer and bring allergen immunotherapy into daily practice with clarity and precision.